Skip to main content
. 2021 Jul 1;5(4):e161. doi: 10.1097/EE9.0000000000000161

Table 3.

Quintile of phthalate and odds of preschool ADHD

Model 1 crudea Model 2adjusted for covariatesb Model 3adjusted for covariates and correlated phthalate metabolitesc
Phthalate Quintile N casesd OR (95% CI) OR (95% CI) OR (95% CI)
MEP 1. <26.0 µg/L 44 ref. ref.
2. 26.0–62.2 µg/L 44 0.96 (0.59 to 1.56) 0.91 (0.54 to 1.53)
3. 62.2–148 µg/L 57 1.28 (0.80 to 2.05) 1.19 (0.72 to 1.95)
4. 148–380 µg/L 55 1.26 (0.79 to 2.01) 1.24 (0.76 to 2.03)
5. >380 µg/L 53 1.18 (0.74 to 1.90) 1.05 (0.63 to 1.75)
Linear modele 253 1.06 (0.96 to 1.17) 1.03 (0.93 to 1.15)
MiBPf 1. <8.76 µg/L 32 ref. ref. ref.
2. 8.76–13.2 µg/L 41 1.30 (0.77 to 2.20) 1.37 (0.79 to 2.39) 1.61 (0.87 to 2.97)
3. 13.2–20.8 µg/L 65 2.07 (1.26 to 3.39) 1.88 (1.12 to 3.18) 2.21 (1.19 to 4.10)
4. 20.8–38.9 µg/L 75 2.32 (1.43 to 3.78) 2.37 (1.41 to 3.99) 2.77 (1.46 to 5.25)
5. >38.9 µg/L 40 1.23 (0.73 to 2.09) 1.19 (0.68 to 2.08) 1.29 (0.65 to 2.57)
Linear modele 253 1.10 (0.93 to 1.30) 1.08 (0.89 to 1.29) 0.98 (0.78 to 1.24)
MnBP 1. <9.90 µg/L 49 ref. ref. ref.
2. 9.90–14.6 µg/L 41 0.83 (0.51 to 1.35) 0.76 (0.45 to 1.27) 0.54 (0.30 to 0.97)
3. 14.6–21.9 µg/L 48 0.96 (0.60 to 1.55) 0.92 (0.56 to 1.52) 0.55 (0.29 to 1.03)
4. 21.9–34.0 µg/L 55 1.17 (0.74 to 1.85) 1.10 (0.67 to 1.80) 0.59 (0.31 to 1.14)
5. >34.0 µg/L 60 1.22 (0.77 to 1.93) 1.15 (0.70 to 1.89) 0.64 (0.32 to 1.30)
Linear modele 253 1.17 (0.97 to 1.41) 1.18 (0.95 to 1.45) 1.13 (0.84 to 1.52)
MBzP 1. <2.19 µg/L 40 ref. ref. ref.
2. 2.19–3.46 µg/L 40 1.06 (0.64 to 1.76) 0.93 (0.54 to 1.59) 0.93 (0.52 to 1.69)
3. 3.46–5.51 µg/L 53 1.36 (0.84 to 2.22) 1.27 (0.76 to 2.13) 1.28 (0.71 to 2.30)
4. 5.51–9.60 µg/L 54 1.40 (0.86 to 2.27) 1.40 (0.83 to 2.33) 1.41 (0.75 to 2.66)
5. >9.60 µg/L 66 1.70 (1.06 to 2.72) 1.39 (0.83 to 2.31) 1.37 (0.71 to 2.64)
Linear modele 253 1.19 (1.01 to 1.40) 1.13 (0.95 to 1.35) 1.07 (0.85 to 1.35)
∑DEHP 1. <0.16 µmol/L 41 ref. ref. ref.
2. 0.16–0.21 µmol/L 52 1.34 (0.83 to 2.17) 1.26 (0.76 to 2.09) 1.28 (0.76 to 2.15)
3. 0.21–0.27 µmol/L 49 1.23 (0.75 to 2.01) 1.23 (0.73 to 2.06) 1.15 (0.68 to 1.97)
4. 0.27–0.38 µmol/L 47 1.21 (0.74 to 1.97) 1.23 (0.73 to 2.06) 1.19 (0.70 to 2.03)
5. >0.38 µmol/L 64 1.59 (0.99 to 2.54) 1.58 (0.96 to 2.61) 1.51 (0.89 to 2.56)
Linear modelf 253 1.17 (0.96 to 1.43) 1.22 (0.99 to 1.52) 1.18 (0.93 to 1.49)
∑DiNPf 1. <0.012 µmol/L 42 ref. ref. ref.
2. 0.012–0.016 µmol/L 76 1.82 (1.15 to 2.88) 2.07 (1.27 to 3.37) 2.04 (1.25 to 3.33)
3. 0.016–0.020 µmol/L 35 0.88 (0.53 to 1.47) 0.89 (0.52 to 1.55) 0.86 (0.50 to 1.50)
4. 0.020–0.027 µmol/L 42 1.01 (0.61 to 1.66) 1.13 (0.67 to 1.92) 1.07 (0.62 to 1.82)
5. >0.027 µmol/L 58 1.37 (0.85 to 2.20) 1.70 (1.03 to 2.82) 1.54 (0.91 to 2.61)
Linear modele 253 1.11 (0.89 to 1.39) 1.18 (0.94 to 1.49) 1.10 (0.85 to 1.42)

aAdjusted for specific gravity, analytic batch.

bAdjusted for specific gravity, analytic batch, child sex and maternal age, education, parity, depression during pregnancy, and ADHD-like symptoms.

cAdjusted for specific gravity, analytic batch, child sex and maternal age, education, parity, depression during pregnancy, ADHD-like symptoms and additionally adjusted for correlated metabolites (a) MiBP, MnBP, and MBzP co-adjusted for one another; (b) ∑DEHP and ∑DiNP coadjusted for each other).

dNumber with no missing exposure or covariates in Model 2.

ePer 1 natural log-unit increase in biomarker.

fAssociated nonlinearly (Wald test P < 0.10) for MiBP and ∑DiNP when modeled using Model 2 adjustment set and restricted cubic splines with knots at 20th, 40th, 60th, and 80th percentiles.